Ogenx Therapeutics Corp

Multi-drug platform with novel mechanism of action for difficult to treat diseases; currently pursuing canine cancers

  • Stage Product In Development
  • Industry Biotechnology
  • Location Clearwater, FL, USA
  • Currency USD
  • Founded July 2012
  • Employees 2
  • Website ogenx.com

Company Summary

Using a compound from its 35-drug Redoxagen™ platform, RC-1 alpha, Ogenx is pursuing a huge market opportunity for treatment of Dry Age-Related Macular Degeneration, a leading cause of blindness with no current treatment. A separate Redoxagen compound, RC-2 beta, is being developed for canine lymphosarcoma and mast cell tumors under FDA MUMS designation, providing near-term value inflection points and greatly accelerated route to market.

Team

  • Richard Davis, MD
    Chief Executive Officer

    Formerly: Chrm, Pres & CEO, EquinOx Pharmaceuticals, Inc.; Chrm, Pres & CEO, PhereSys Therapeutics; Chrm, Pre, CEO & Co-Founder, OccuLogix; Chrm, Pres CEO & Founder, UroQuest; Chrm, Pres, CEO & Founder, Code Blue Medical Education: MD, Medical College of Virginia; BSc, Chemistry, Old Dominion Univ.; Service: Flight Surgeon USN (back-up Blue Angels); Hyperbaric Diving Officer (USN Seals)

  • Peter Urrea, Ph.D.
    Chief Regulatory Officer and SVP Clinical

    Formerly: Global Head Breast Cancer Development, Stanford Research Institute; SVP Clinical & Regulatory Affairs, Taiho Pharma USA; VP Clinical Operations, Sugen (acquired by Pharmacia, then Pfizer); Head of Drug Development Operations, Oraquest, Inc.; VP Operations, Hydrocurve; VP R&D, Barnes-Hind Pharmaceuticals, Inc. Education: Ph.D., UCSF; Pharm.D., UCSF; B.S., Univ. Calif., Berkeley

  • Dmytro Berezhnoy, Ph.D., MBA
    Chief Scientific Officer

    Formerly: Director of Strategic Development, eBiochemia.com; Head of Operations at HTEP Screening Center, Boson University Education: MBA, Finance/Marketing, HEC, Montreal; Ph.D. Pharmacology/Neuroscience, University of Bern, Switzerland; B.Sc./M.Sc., Organic Chemistry, I.I. Mechnikov National University, Odessa, Ukraine

  • Dmytro Berezhnoy

Advisors

  • General: Lowenstein Sandler, PC; Patent: Jackson Walker LLP; FDA: Olsson Frank Weeda Terman
    Lawyer
    Unconfirmed
    Not yet appointed
    Accountant
    Unconfirmed

Previous Investors

  • Cyrus Capital Management (In predessor company)
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free